製藥、生物技術和診斷產業的併購交易（2021-2026）

全球生命科學產業併購策略基準分析

"製藥、生物技術和診斷產業的併購交易（2021-2026）" 報告對全球生命科學產業的併購活動進行了全面分析。本報告專為企業發展、業務拓展、投資和策略領域的專業人士設計，深入剖析了企業如何建立併購交易以及如何就交易背後的財務條款進行談判。

這份經過全面修訂和更新的報告分析了2021年1月至2026年3月期間宣布的2500多筆併購交易，全面展現了製藥、生物技術和診斷公司的收購活動。

每筆交易都包含指向詳細線上合約記錄的鏈接，並且在條件允許的情況下，還會提供提交給監管機構的原始合約。透過整合全面的合約資料、財務基準和合約存取權限，本報告提供了寶貴的見解，幫助您評估收購機會、衡量合約價值並了解產業整合策略。

主要優勢

• 顯著縮短研究時間

在一個集中式資源中存取超過2500筆併購交易。無需再搜尋多個資料庫、新聞稿和監管文件。

• 收購結構與估值基準分析

了解製藥、生技和診斷設備公司如何建構收購方案，包括現金協議、股權協議和混合結構。

• 自信分析合約價值

審查已揭露的合約金額和財務條款，並比較類似交易中的收購價格和合約結構。

• 查閱實際合約文件

如有需要，請參考向美國證券交易委員會 (SEC) 提交的併購協議，以深入了解實際協議背後的詳細合約條款。

• 辨識最活躍的收購方

辨識出引領產業重組的關鍵參與者，並分析其收購策略。

• 追蹤產業整合趨勢

分析各公司、治療領域和技術領域的併購活動，以了解生命科學產業的演變。

回報內容

2021年以來併購交易趨勢分析

併購交易結構概述

基於已揭露交易價值的重大收購交易回顧

最活躍的收購者和交易撮合者簡介

依公司、治療領域、技術類型和行業細分市場進行的詳細交易分析

2021年以來已公佈的併購交易綜合目錄

線上交易記錄和交易文件連結（如有）

基於實際合約的盡職調查見解

本報告允許使用者評估關鍵合約條款，例如：

• 資產和公司收購結構
• 收購價格以及付款方式
• 智慧財產權轉讓條款
• 獲利支付結構與有條件付款
• 業務整合責任範圍
• 交割條件與終止條款
• 查閱實際合約能夠深入了解公司間談判的詳細條款。這些資訊很少在新聞稿或傳統合約資料庫中披露。
• 本報告的重要性
• 對於製藥和生技公司而言，併購是拓展產品線、取得創新技術和加速成長的關鍵策略。生命科學產業每年都會出現大規模的併購活動，各公司都在尋求策略性收購，以增強其產品組合和能力。 本報告結合了全面的收購數據、合約基準分析以及對實際合約文件的查閱，為評估收購機會、了解行業整合趨勢以及進行更有效的談判提供了必要的洞察。

目錄

摘要整理

第一章：引言

第二章：併購合約趨勢

• 引言
• 合併與收購的差異
• 2021年以來併購合約趨勢
  • 2021年以來併購合約數（年度）
  • 2021年以來各行業的併購合約狀況
  • 2021年以來各治療領域的併購合約
  • 2021年以來最活躍公司的併購合約
• 主要併購趨勢
• 新的收購：是否有收購選擇？
• 何時進行併購可行
• 併購協議的特徵
  • 併購作為IPO的替代方案
• 包含併購要素的合夥協議
  • 合夥作為併購的預備階段
  • 合夥協議中的股權部分
  • 從合夥到收購的過渡
  • 然而，併購並非總是首選路徑
• 大型製藥公司的大規模合併－末日將至？
  • 強生公司透過併購實現成長
  • 諾華公司透過併購實現成長
• 透過併購獲取創新
  • 大藥廠收購中小企業
  • 中小型生物製藥公司－利用併購
  • 利用併購組成公司
  • 生技公司合併的興起
• 私募股權在併購中的新角色
• 併購協議的執行
• 合資企業作為併購的替代方案
• 生物製藥併購的未來

第三章 併購協議結構概述

• 引言
• 純收購協議與多組分收購協議
• 純併購協議結構
• 作為更廣泛合作協議一部分的收購
• 合併協議

第四章 - 重大併購交易

• 引言
• 以價值排名的頂級併購交易

第五章 - 最活躍的25家併購公司

• 引言
• 最活躍的25家併購公司

第六章 - 2021年以來的併購交易目錄

• 引言
• 2021年以來簽訂的併購交易
• 交易目錄
• 依公司（AZ）分類的併購交易目錄
• 依治療領域分類的併購交易目錄
• 交易類型定義
• 關於我們研究公司
• 當前合作夥伴關係
• 當前交易
• 來自 Current Partnership 的最新報告標題

Benchmark Acquisition Strategies Across the Global Life Sciences Industry

The Merger and Acquisition (M&A) Deals in Pharmaceuticals, Biotechnology and Diagnostics 2021-2026 report provides a comprehensive analysis of acquisition activity across the global life sciences sector. Designed for corporate development, business development, investment, and strategy professionals, the report delivers detailed insight into how companies structure mergers and acquisitions and negotiate the financial terms behind these transactions.

Fully revised and updated, the report analyzes 2,500+ M&A agreements announced between January 2021 and March 2026, offering an extensive view of acquisition activity across pharmaceutical, biotechnology, and diagnostics companies.

Each transaction links to a detailed online deal record and, where available, the original contract documents filed with regulators. By combining comprehensive deal data, financial benchmarking, and contract access, the report provides valuable intelligence for evaluating acquisition opportunities, benchmarking transaction values, and understanding industry consolidation strategies.

Key Benefits

• Save Significant Research Time

Access over 2,500 M&A deals in one consolidated resource, eliminating the need to search multiple databases, press releases, and regulatory filings.

• Benchmark Acquisition Structures and Valuations

Understand how pharmaceutical, biotechnology, and diagnostics companies structure acquisitions, including cash transactions, equity deals, and hybrid structures.

• Analyze Transaction Values with Confidence

Review disclosed deal values and financial terms to benchmark acquisition prices and transaction structures across comparable deals.

• Access Real Contract Documents

Where available, explore SEC-filed merger and acquisition agreements, providing insight into the detailed contractual provisions behind real transactions.

• Identify the Most Active Acquirers

Discover which companies are leading consolidation activity and analyze their acquisition strategies.

• Track Industry Consolidation Trends

Analyze M&A activity across companies, therapeutic areas, and technology sectors to understand how the life sciences industry is evolving.

What's Included in the Report

Analysis of M&A dealmaking trends since 2021

Overview of merger and acquisition transaction structures

Review of leading acquisitions by disclosed deal value

Profiles of the most active acquirers and dealmakers

Detailed analysis of deals by company, therapeutic area, technology type, and industry segment

A comprehensive directory of M&A transactions announced since 2021

Links to online deal records and contract documents where available

Due Diligence Insights from Real Agreements

By reviewing actual merger and acquisition contracts, the report enables users to evaluate key transaction provisions such as:

• Asset and company acquisition structures
• Purchase price and payment mechanisms
• Intellectual property transfer provisions
• Earn-out structures and contingent payments
• Operational integration responsibilities
• Transaction closing conditions and termination clauses
• Access to real agreements provides insight into the detailed terms negotiated between companies-information rarely disclosed in press releases or traditional deal databases.
• Why This Report Matters
• Mergers and acquisitions are a critical strategy for pharmaceutical and biotechnology companies seeking to expand pipelines, acquire innovative technologies, and accelerate growth. The life sciences industry experiences significant M&A activity each year as companies pursue strategic acquisitions to strengthen their portfolios and capabilities.
• By combining comprehensive acquisition data, transaction benchmarking, and access to real contract documents, this report provides the intelligence needed to evaluate acquisition opportunities, understand industry consolidation trends, and negotiate more effectively.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in M&A dealmaking

• 2.1. Introduction
• 2.2. Difference between merger and acquisition deals
• 2.3. Trends in M&A deals since 2021
  • 2.3.1. M&A dealmaking by year since 2021
  • 2.3.2. M&A dealmaking by industry sector since 2021
  • 2.3.3. M&A dealmaking by therapy area since 2021
  • 2.3.4. M&A dealmaking by most active company since 2021
• 2.4. Key M&A trends
• 2.5. Option to acquire the new acquisition?
• 2.6. When M&A can be useful
• 2.7. Attributes of M&A deals
  • 2.7.1. M&A as an alternative to IPO
• 2.8. Partnering deals with M&A component
  • 2.8.1. Partnering as a precursor to M&A
  • 2.8.2. Equity as part of partnering deal
  • 2.8.3. Conversion of partnership to acquisition
  • 2.8.4. But M&A is not always the route followed
• 2.9. Big pharma mega mergers - are we at the end of the road?
  • 2.9.1. Growth of Johnson & Johnson through M&A
  • 2.9.2. Growth of Novartis through M&A
• 2.10. Accessing innovation through M&A
  • 2.10.1. Big pharma acquisitions of small companies
  • 2.10.2. Medium and small biopharma - use of M&A
  • 2.10.3. Using M&A to build a company
  • 2.10.4. Emergence of biotech-biotech mergers
• 2.11. The emerging role of private equity in M&A
• 2.12. Implementing M&A transactions
• 2.13. Joint ventures as alternative to M&A
• 2.14. The future of M&A in biopharma

Chapter 3 - Overview of M&A deal structure

• 3.1. Introduction
• 3.2. Pure versus multi-component acquisition deals
• 3.3. Pure M&A agreement structure
• 3.4. Acquisition as part of a wider alliance agreement
• 3.5. Merger agreements

Chapter 4 - Leading M&A deals

• 4.1. Introduction
• 4.2. Top M&A deals by value

Chapter 5 - Top 25 most active M&A dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active M&A dealmakers

Chapter 6 - M&A contract directory since 2021

• 6.1. Introduction
• 6.2. M&A deals with contracts since 2021
• Deal Directory
• Deal Directory - M&A deals by company A-Z
• Deal Directory - M&A deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of merger and acquisition
• Figure 2: Trends in M&A deal announcements
• Figure 3: M&A deals by industry sector
• Figure 4: M&A deals by therapy area
• Figure 5: Top 50 most active M&A dealmakers
• Figure 6: Key recent M&A trends
• Figure 7: Situations where M&A can prove useful
• Figure 8: Recent partnering deals involving equity participation in the licensor
• Figure 9: Equity investments converting to acquisitions
• Figure 10: Issues in implementing M&A agreements
• Figure 11: Future trends in M&A in biopharma
• Figure 12: Components of the acquisition deal structure
• Figure 13: Components of the merger deal structure
• Figure 14: Top M&A deals by value
• Figure 15: Most active M&A dealmakers